{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:32:35Z","timestamp":1759847555588},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal impairment may be associated with an increased risk of hematologic events (AEs) in patients undergoing treatment with trifluridine\/tipiracil (FTD\/TPI). This study aimed to investigate the specific types of AEs linked to renal impairment in patients with metastatic colorectal cancer (mCRC) receiving FTD\/TPI, using real-world data. Among the patients included in the REGOTAS study (a retrospective study of FTD\/TPI versus regorafenib), those treated with FTD\/TPI were evaluated. Creatinine clearance values of &lt;\u200930, 30\u201360, 60\u201390, and\u2009&gt;\u200990\u00a0mL\/min were defined as severe, moderate, mild renal impairment, and normal renal function, respectively. Renal impairment was analyzed as a risk factor for grade 3 or higher AEs using a logistic regression model. Overall survival (OS) and progression-free survival (PFS) based on renal impairment were evaluated. A total of 309 patients were included in the analysis, with 124, 130, and 55 patients divided into the normal, mild, and moderate-to-severe groups, respectively. The risk of grade 3 or higher neutropenia was significantly higher in the moderate-to-severe group (odds ratio 3.47; 95% confidence interval 1.45\u20138.30; <jats:italic>P<\/jats:italic>\u2009=\u20090.005), but there was no significant increase in the risk of non-hematologic AEs in any of the groups. The OS and PFS of patients in the mild and moderate-to-severe groups were comparable to those in the normal group. Patients with mCRC and moderate\/severe renal impairment receiving FTD\/TPI therapy may develop severe neutropenia; however, FTD\/TPI remains a viable treatment option due to its clinical benefit.<\/jats:p>","DOI":"10.1038\/s41598-023-45244-7","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T09:03:01Z","timestamp":1697792581000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Renal impairment as a risk factor for trifluridine\/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study"],"prefix":"10.1038","volume":"13","author":[{"given":"Mamiko","family":"Shiroyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kumekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"45244_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45244_CR2","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka, N. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol. Rep. 32, 2319\u20132326 (2014).","journal-title":"Oncol. Rep."},{"key":"45244_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","volume":"88","author":"MW Saif","year":"2021","unstructured":"Saif, M. W. et al. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother. Pharmacol. 88, 485\u2013497 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"45244_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jjco\/hyaa243","volume":"51","author":"T Yoshino","year":"2021","unstructured":"Yoshino, T. et al. Post-marketing surveillance study of trifluridine\/tipiracil in patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 51, 700\u2013706 (2021).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"45244_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","volume":"23","author":"T Moriwaki","year":"2018","unstructured":"Moriwaki, T. et al. Propensity Score Analysis of Regorafenib Versus Trifluridine\/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 23, 7\u201315 (2018).","journal-title":"Oncologist"},{"key":"45244_CR6","unstructured":"Cancer Therapy Evaluation Program, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (2010)."},{"key":"45244_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13, 993\u20131001 (2012).","journal-title":"Lancet Oncol"},{"key":"45244_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"key":"45244_CR9","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.esmoop.2022.100633","volume":"7","author":"E Van Cutsem","year":"2022","unstructured":"Van Cutsem, E. et al. Pooled safety analysis from phase III studies of trifluridine\/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. ESMO Open 7, 100633 (2022).","journal-title":"ESMO Open"},{"key":"45244_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s10120-021-01271-9","volume":"25","author":"K Shitara","year":"2022","unstructured":"Shitara, K. et al. Efficacy and safety of trifluridine\/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: Subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer 25, 586\u2013597 (2022).","journal-title":"Gastric Cancer"},{"key":"45244_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino, T. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann. Oncol. 31, 88\u201395 (2020).","journal-title":"Ann. Oncol."},{"key":"45244_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jjco\/hys235","volume":"43","author":"Y Funakoshi","year":"2013","unstructured":"Funakoshi, Y. et al. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn. J. Clin. Oncol. 43, 271\u2013277 (2013).","journal-title":"Jpn. J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45244-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:28:37Z","timestamp":1700490517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45244-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45244"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45244-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Toshiki Masuishi received honoraria from Taiho. Atsuo Takashima received honoraria from Eli Lilly, Ono, Taiho, Takeda, and Chugai, and received research funding from Daiichi, Ono, Bristol Myers, and MSD. Takeshi Kajiwara received lecture fees from Eli Lilly, Chugai, and Bristol-Myers Squibb. Kentaro Yamazaki received honoraria from Chugai, Takeda, Yakult, Taiho, Daiichi Sankyo, Bayer, Merck Serono, Eli Lilly, Sanofi, Ono, MSD, and Bristol Myers, and research funding from Taiho. Taito Esaki received honoraria from Chugai, Daiichi Sankyo, Taiho, and research funding from Daiichi Sankyo, Chugai, Amgen, Ono, Pfizer, Novartis, Astellas, Astellas Amgen Biopharma, Quintiles, AsahikaseiPharma, Syneos Health, and IQVIA. Akitaka Makiyama received honoraria from Eli Lilly, Taiho, Ono, Bristol-Myers Squibb, and Daiichi Sankyo. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17931"}}